Personalized, biomarker-guided allogeneic chimeric antigen receptor

Class

Personalized, biomarker-guided allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy — single- or dual-target construct selected per-patient after tumor antigen profiling (tissue/liquid biopsy)

Pathway

NK-cell-mediated cytotoxicity against a patient-specific tumor antigen (candidate antigens include CD30, CD5, mesothelin)

Notes

original target text: Personalized, biomarker-guided allogeneic chimeric antigen receptor (CAR) natural killer (NK) cell therapy — single- or dual-target construct selected per-patient after tumor antigen profiling (tissue/liquid biopsy)

This mechanism refers to a class of cell-based cancer therapies built from natural killer (NK) cells, an arm of the innate immune system capable of killing abnormal cells without prior antigen exposure. Here, NK cells are engineered with a chimeric antigen receptor (CAR), a synthetic receptor that redirects their cytotoxic activity toward a specific tumor-associated protein. What distinguishes this approach is its personalized, biomarker-guided design: a patient's tumor is profiled through tissue or liquid biopsy to identify which antigen it expresses (candidates include CD30, CD5, or mesothelin), and a CAR construct matching that antigen, or two antigens in a dual-target design, is selected for that individual. The cells themselves are allogeneic, meaning sourced from a healthy donor rather than the patient, which allows manufacturing in advance rather than custom production for each person. The overall rationale is to concentrate cytotoxic activity precisely on tumor cells bearing the chosen marker while minimizing damage to healthy tissue, and to address the reality that different tumors, even within the same cancer type, express different surface antigens. This approach is relevant across hematologic malignancies and solid tumors where antigen expression is heterogeneous among patients.